Corpus Intelligence IC Memo — BRYLIN HOSPITALS 2026-04-26 14:10 UTC
IC Memo — BRYLIN HOSPITALS
Investment Committee Memorandum | NY | 88 beds | Grade D | EBITDA uplift $1.3M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

BRYLIN HOSPITALS

CCN 334022 | ERIE, NY | 88 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

BRYLIN HOSPITALS is a 88-bed under-performing / distressed in ERIE, NY with $17.3M in net patient revenue and a -9.7% operating margin. The hospital serves a payer mix of 7.1% Medicare, 1.7% Medicaid, and 91.2% commercial.

Thesis: Turnaround. Our ML models identify $1.3M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -9.7% to -2.4% (+736bps).

Net Revenue HCRIS$17.3M
Current EBITDA COMPUTED$-1.7M
Operating Margin COMPUTED-9.7%
Occupancy HCRIS37.0%
Revenue / Bed COMPUTED$197K
Net-to-Gross HCRIS58.7%
Distress Probability ML54.3%

2. Market Context & Competitive Position

196
NY Hospitals
-17.5%
State Median Margin
67
Comparable Hospitals

NY has 196 Medicare-certified hospitals with a median operating margin of -17.5%. The target's margin of -9.7% places it above the state median. Among 67 size-comparable peers (44-176 beds), the median margin is -18.3%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (44-176), prioritizing same-state peers. 67 hospitals in the comp set.

HospitalStateBedsRevenueMargin
BRYLIN HOSPITALS (Target)NY88$17.3M-9.7%
ROSWELL PARK CANCER INSTITUTENY142$772.3M-40.1%
MARY IMOGENE BASSETT HOSPITALNY160$529.1M-31.6%
SARATOGA HOSPITALNY171$431.9M-12.3%
NORTHERN WESTCHESTER HOSPITALNY162$416.0M-4.5%
OUR LADY OF LOURDES MEMORIAL HNY175$411.8M-24.9%
PHELPS MEMORIAL HOSPITAL CENTENY135$360.4M-20.4%
CAYUGA MEDICAL CENTER AT ITHACNY107$302.3M-13.1%
PECONIC BAY MEDICAL CENTERNY130$294.3M-9.3%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $1.3M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$364K+210bp18mo
Cost to Collect4.5%2.5%$347K+200bp12mo
Denial Rate Reduction12.0%6.5%$343K+198bp12mo
A/R Days Reduction5200.0%3800.0%$211K+122bp9mo
Clean Claim Rate88.0%96.0%$11K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$364K
Cost to Collect
$347K
Denial Rate Reduction
$343K
A/R Days Reduction
$211K
Clean Claim Rate
$11K
Total EBITDA Uplift$1.3M
Current EBITDA$-1.7M
+ RCM Uplift+$1.3M
Pro Forma EBITDA$-412K
Current Margin-9.7%
Pro Forma Margin-2.4%
WC Released (1x)$665K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-2.6M$1.6M0.00x-100.0%
Base (11x exit)10.0x11.0x$-2.6M$945K0.00x-100.0%
Bull Case9.0x11.0x$-2.3M$4.3M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-2.3M$4.0M0.00x-100.0%
Bear Case11.0x10.0x$-2.9M$-3.9M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-2.9M$-5.2M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
HighElevated distress probabilityModel estimates 54.3% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 67 hospitals with 44-176 beds
  • Same-state prioritization (n=68)
  • Comp margins: P25=-29.8% / P50=-18.3% / P75=-9.3%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.